Andras A. Heczey, MD
Department or Service
- Texas Medical Center
- Liver Tumors
Director, Liver Tumor Program
Assistant Professor, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
|Baylor College of Medicine||fellowship||Pediatric Hematology Oncology||2012|
|Children's Hospital of Los Angeles||residency||Pediatrics||2009|
|Semmelweis Medical University, Hungary||residency||Infectious Disease||2006|
|Semmelweis University||medical school||Doctor of Medicine||2002|
Dr. Andras Heczey is a physician-scientist and full-time faculty in the Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology/Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT).
General Pediatrics, American Board of Pediatrics
Pediatric Hematology and Oncology, American Board of Pediatrics
|American Society of Cell and Gene Therapy (ASCGT)||Member|
|American Society of Clinical Oncology (ASCO)||Member|
|American Society of Pediatric Hematology and Oncology (ASPHO)||Member|
|Children's Oncology Group (COG)||Member|
Dr. Andras Heczey's research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack and kill cancer cells by using genetically-engineered T cells and Natural Killer T cells.
As the Director of the Liver Tumor Center, Dr. Heczey developed a strategy to target hepatoblastoma and hepatocellular carcinoma with genetically-engineered T lymphocytes. He is currently optimizing this strategy for a smooth transition into the clinic. He developed bispecific T cell engagers and chimeric antigen receptors which specifically target hepatoblastoma and hepatocellular carcinoma when expressed in T cells. His goal is to cure all patients with liver cancers by translating these methods from the laboratory setting to the patient care clinic.
In regards to neuroblastoma, Dr. Heczey studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells (NKT cells) that are genetically-modified to attack neuroblastoma. He aims to transition this approach from bench-to-bedside as a Phase 1/2a clinical trial.
2000 Good Student and Good Athlete of the Republic of Hungary, Ministry of Education of Hungary
2009 Associates and Affiliates Award of the Children's Hospital of Los Angeles, for scientific knowledge, clinical judgment and excellence in human relations
2010 Tumor Board Award, Texas Children's Cancer and Hematology Centers
2011-2012 Chief Fellow, Texas Children's Cancer and Hematology Centers
2015 Fellows’ Excellence in Education Award, Texas Children's Cancer and Hematology Centers
2017 Faculty Recognition Award, Texas Children’s Cancer and Hematology Centers
2017 Biotherapeutics Award, Alex's Lemonade Stand Foundation